$4.65
-0.25 (-5.10%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CAMP is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 5 tracked-famous managers (Balyasny Asset Management L.P., TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, Hudson Bay Capital Management LP, MARSHALL WACE, LLP) · FINRA short interest 8.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of CMP-CPS-001 in Healthy Volunteers and Participants With Abnormal Heterozygous OTC GenotypeNCT06247670Adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Active, not recruiting | Drug: CMP-CPS-001 · Other: Placebo | Healthy Volunteers, OTC Deficiency | 120 | Dec 2027 | ≤ 498 d | 2026-04-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19